{"name":"AngioLab, Inc.","slug":"angiolab-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOZVRUM09NbTMwZlBrNENqbXZUTnl1Y0VLajdSZG9iZGdfQ3Nabl95RFJ5R3F3UUVGRURYaFBsTmZRaDdoY21NWmU3WEhZWXBldmFiYk1QeEpjZGlwN2lvWWpvY1QyaUhIQVZ0MU9YOHNjbDR0d3ZSckNWVUZDUkx5dkl0NTAybjVfQ2Z2OVRLbUFKa2hRUEFOZ0lqQjl6aG9QYzJHQkZZNTBLYUdyZXNmcmRFaGhYQ29sOXhZQnJCOGlKa0VOOGR0STZzTFBmZW5QOE0xN3pKMGlLcV9XSFBGMGp4X05EUERPdHRsaE1SdmFBWFloM05vbTZXSFNFdw?oc=5","date":"2024-01-17","type":"pipeline","source":"IANS","summary":"Indo-Asian News Service - IANS","headline":"Indo-Asian News Service","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6wFBVV95cUxPOXduWVp5b19OWFd5R1BzMkZvcldONC0xVEc3NTh1aEhJLU5HV1Q0Ni0zZlVxUGFzemZoRzBWdmVPOUJ0eXVnZVdKeGtQVTlQMmJNdEwzaWptc2puZTg2dFM5Vkk1XzlUX3R6bjllTTRVeGhzcGlzVTdkNXk0amx3bS1HWUY1UHdWOFlCNnhqS2ZlLVVhRmdHQWhDV3VncVRDcUlpUnU5b204Q3BEazN3bXRBclJZdDByMjQxNDZCX3RIWG9UVWc3YlV6Uk9UWGUyeGUyUmhlbEV0ZjVfYlJmbGVYMDR5YXBFeXAw?oc=5","date":"2023-07-12","type":"pipeline","source":"PR Newswire","summary":"Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight - PR Newswire","headline":"Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}